Loading…
Aardvark Therapeutics, Inc. is projected to decline to $3.58 by 2027, a -10% move from its current price of $3.99. AARD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.76 | $3.99 | $4.23 | -0.04% |
| May 30 | $3.67 | $3.99 | $4.33 | -0.08% |
| May 31 | $3.61 | $3.99 | $4.40 | -0.12% |
| Jun 1 | $3.55 | $3.98 | $4.47 | -0.16% |
| Jun 2 | $3.50 | $3.98 | $4.53 | -0.20% |
| Jun 3 | $3.45 | $3.98 | $4.59 | -0.24% |
| Jun 4 | $3.41 | $3.98 | $4.64 | -0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.41 | $3.98 | $4.64 | -0.28% |
| Week 2 | $3.20 | $3.97 | $4.93 | -0.56% |
| Week 3 | $3.04 | $3.96 | $5.16 | -0.85% |
| Week 4 | $2.91 | $3.95 | $5.36 | -1.13% |
| Week 5 | $2.79 | $3.93 | $5.54 | -1.41% |
| Week 6 | $2.70 | $3.92 | $5.70 | -1.68% |
| Week 7 | $2.61 | $3.91 | $5.86 | -1.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aardvark Therapeutics, Inc. (AARD) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company was incorporated in 2017 and is headquartered in San Diego, California.
The description places Aardvark in the Healthcare sector. Its stock identity and activities are presented as a publicly traded biotech enterprise operating in this space.
Aardvark Therapeutics, Inc. is currently priced at $3.99 per share. Its market capitalization is $87.05M and it ranks 4258 by market cap.
The near-term technical picture is bearish, with RSI(14) at 40. The 50-day simple moving average is $4.79, and the 200-day simple moving average is $9.95. The price currently sits on a near-term support of $3.99 and faces resistance at $6.73.
The 30-day price range runs from a low of $2.73 to a high of $5.84, highlighting recent volatility within a relatively tight trading corridor.
A major floor 45.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 68.7% above — a clean break opens room to run.
A major ceiling 296.5% above — clearing it would confirm fresh momentum.
Key AARD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AARD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.31 | Sell | $4.32 | Sell |
| MA 10 | $4.82 | Sell | $4.63 | Sell |
| MA 20 | $5.19 | Sell | $4.92 | Sell |
| MA 50 | $4.79 | Sell | $5.67 | Sell |
| MA 100 | $8.27 | Sell | $7.25 | Sell |
| MA 200 | $9.95 | Sell | $9.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.42 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -119.69 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -26.65 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | -0.81 | Sell |
| Ultimate (7,14,28) | 28.60 | Buy |
| Momentum (10) | -2.12 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 4.14 | Sell |
| ADX (14) | 19.73 | Neutral |
| ATR (14) | 0.30 | Info |
The 30-day technical picture shows bearish sentiment. The RSI(14) is 40, signaling modest bearish momentum.
The SMA50 is $4.79 and the SMA200 is $9.95, indicating the longer-term average remains well above the near-term level. A near-term support is at $3.99 and resistance is at $6.73, framing a limited upside potential unless momentum shifts.
The 30-day range is $2.73 to $5.84, illustrating the price trades within a modestly widening band and a vulnerable position near the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.51 | $3.99 | $6.11 | 0% | Neutral | |
| $2.51 | $3.58 | $5.53 | -10% | Neutral | |
| $2.52 | $3.84 | $6.35 | -4% | Neutral | |
| $2.28 | $3.70 | $6.43 | -7% | Neutral | |
| $1.99 | $3.41 | $6.18 | -15% | Neutral | |
| $2.46 | $4.44 | $8.35 | +11% | Neutral | |
| $2.84 | $5.39 | $10.46 | +35% | Bullish | |
| $2.94 | $5.84 | $11.69 | +46% | Bullish | |
| $2.67 | $5.57 | $11.45 | +40% | Bullish | |
| $2.27 | $4.96 | $10.44 | +24% | Bullish | |
| $3.51 | $7.80 | $17.94 | +96% | Bullish | |
| $5.13 | $11.40 | $26.23 | +186% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.51 | $3.99 | $4.74 | +0.00% |
| June 2026 | $3.15 | $3.79 | $4.75 | -4.91% |
| July 2026 | $3.13 | $3.85 | $4.95 | +1.36% |
| August 2026 | $3.34 | $4.17 | $5.48 | +8.38% |
| September 2026 | $3.34 | $4.22 | $5.64 | +1.14% |
| October 2026 | $3.21 | $4.10 | $5.57 | -2.83% |
| November 2026 | $3.29 | $4.25 | $5.85 | +3.64% |
| December 2026 | $3.36 | $4.38 | $6.11 | +3.11% |
Click any year to see its month-by-month AARD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aardvark Therapeutics, Inc.'s 2026 outlook centres on $3.99, within a $3.51 to $6.11 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AARD could reach as high as $5.53, with a base case around $3.58 and support toward $2.51 — roughly -10% from $3.99. Price action looks broadly range-bound.
Expect AARD to range from $2.52 to $6.35 through 2028. The $3.84 average target implies a -4% move from current prices. That is up +7% on the projected 2027 average. A consolidation phase looks the most probable path here.
The AARD price prediction for 2029 points to an average of $3.70 (low $2.28, high $6.43) — a potential decline of -7% on today's $3.99. Price action looks broadly range-bound.
In 2030, AARD is projected to trade between $1.99 and $6.18, averaging $3.41 — a potential decline of -15% from today's $3.99. That is -8% versus the projected 2029 average. A consolidation phase looks the most probable path here.
Aardvark Therapeutics, Inc.'s 2031 outlook centres on $4.44, within a $2.46 to $8.35 range. That is up +30% on the projected 2030 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2032, AARD could reach as high as $10.46, with a base case around $5.39 and support toward $2.84 — roughly +35% from $3.99. Buyers look set to stay in control over this stretch.
Expect AARD to range from $2.94 to $11.69 through 2033. The $5.84 average target implies a +46% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The AARD price prediction for 2034 points to an average of $5.57 (low $2.67, high $11.45) — a potential gain of +40% on today's $3.99. Buyers look set to stay in control over this stretch.
In 2035, AARD is projected to trade between $2.27 and $10.44, averaging $4.96 — a potential gain of +24% from today's $3.99. That is -11% versus the projected 2034 average. Momentum favours further upside here.
Aardvark Therapeutics, Inc.'s 2040 outlook centres on $7.80, within a $3.51 to $17.94 range. That is up +57% on the projected 2035 average. That marks a +96% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AARD could reach as high as $26.23, with a base case around $11.40 and support toward $5.13 — roughly +186% from $3.99. Momentum favours further upside here.
Investing $1,000 in AARD today (≈ 250.626566 AARD) could be worth
$2,857.9
+$1,857.9 (+186%) by 2050 · US Dollar
Based on the average projected AARD price of $11.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AARDwould be worth at today's price.
$1,000 invested in AARD on May 27, 2025 (≈ 101.832997 AARD) would be worth
$406.31
-$593.69 (-59.4%) today · 0.41× · US Dollar
Based on a AARD entry price of $9.82 vs. today's $3.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.29 | $930.07 | -7.0% |
| 1 month ago | $5.52 | $722.83 | -27.7% |
| 3 months ago | $12.5 | $319.2 | -68.1% |
| 6 months ago | $9.98 | $399.8 | -60.0% |
| 1 year ago | $9.82 | $406.31 | -59.4% |
| All time (1.3y) ago | $14.31 | $278.83 | -72.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AARD forecast.
Our base-case forecast reaches $8.00 around 2050.
Implied market cap at $8.00: $174.53M
The multi-year forecast shows a transition from Neutral to Bullish sentiment as time horizons extend. For 2026 the avg price is $3.99 with ROI 0% and Neutral sentiment, followed by 2027 avg $3.58 with ROI -10.3% and Neutral sentiment, and 2028 avg $3.84 with ROI -3.6% and Neutral sentiment.
From 2032 onward the forecast turns Bullish, with 2032 avg $5.39 and ROI 35%, 2033 avg $5.84 and ROI 46.5%, 2034 avg $5.57 and ROI 39.7%, and 2035 avg $4.96 and ROI 24.3%—all labeled Bullish.
The horizon continues to deliver upside: 2040 in the forecast shows avg $7.80 with ROI 95.5% and Bullish sentiment, and 2050 shows avg $11.40 with ROI 185.8% and Bullish sentiment. These figures illustrate meaningful long-term upside but are not guarantees and reflect estimates rather than certainties.
Tap a question to reveal the answer.
The forecast shows an avg price of $3.41, with a min of $1.99 and a max of $6.18, and an expected ROI of -14.6%.
The forecast indicates Neutral sentiment through 2031, with a shift to Bullish from 2032 onward. Notably, longer-horizon years show positive ROI (e.g., 2032 ROI 35%, 2033 ROI 46.5%, 2040 ROI 95.5%, 2050 ROI 185.8%), but early years carry negative or flat ROI.
Yes. The max price in 2033 is $11.69 and in 2034 is $11.45, with earlier high points at $10.46 in 2032. These illustrate potential to surpass $10 in the 2032–2034 window.
The 30-day range is $2.73 to $5.84.
Current price is $3.99. Market capitalization is $87.05M, and the stock ranks 4258 by market cap.
Aardvark Therapeutics, Inc. Community Discussion
0Share your Aardvark Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.